laurolitsine | 65026-58-6

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 阿朴菲
• 英文名称: laurolitsine
• 英文别名: nor-boldine；norboldine；Boldine；1,10-dimethoxy-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,9-diol；1,10-dimethoxy-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,9-diol
• CAS: 65026-58-6
• 化学式: C₁₈H₁₉NO₄
• 分子量: 313.353
• InChiKey: KYVJVURXKAZJRK-UHFFFAOYSA-N

物化性质

• 沸点：
  553.0±50.0 °C(Predicted)
• 密度：
  1.313±0.06 g/cm3(Predicted)
• 物理描述：
  Solid
• 熔点：
  138-140°C

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  71
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  laurolitsine 在 ammonium acetate 、 potassium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 8-(2-(Butylamino)ethyl)-3,5-dimethoxyphenanthrene-2,6-diol
  参考文献：
  名称：

  Litebamine N-Homologues:  Preparation and Anti-Acetylcholinesterase Activity

  摘要：

  Litebamine N-homologues were easily prepared from laurolitsine, generally via three reaction steps (N-alkylation, solvolysis with 1 M NH4OAc under reflux, and the Mannich reaction) in more than 80% overall yield. Among the prepared compounds, N-propyl-, N-isobutyl-, and N-isopropylnorlitebamines exhibited moderate antiacetylcholinesterase activity (IC50 Ca 7.0 mu M), while the corresponding N-metho salt of N-propylnorlitebamine showed potent activity (IC50 2.70 mu M).

  DOI：

  10.1021/np970298f

文献信息

• WO2007/134485
  申请人：——

  公开号：——

  公开（公告）日：——
• Bick, I. Ralph C.; Sevenet, Thierry; Sinchai, Wannee, Australian Journal of Chemistry, 1981, vol. 34, # 1, p. 195 - 207
  作者：Bick, I. Ralph C.、Sevenet, Thierry、Sinchai, Wannee、Skelton, Brian W.、White, Allan H.

  DOI：——

  日期：——
• Method for Treating Nervous System Injuries Using Boldine and Analogs Thereof
  申请人：United States Government as Represented by the Department of Veterans Affairs

  公开号：US20210251979A1

  公开（公告）日：2021-08-19

  Provided are methods of treating an injury to the nervous system in a subject comprising administering to the subject an effective amount of boldine, a boldine analog, or a pharmaceutically-acceptable salt thereof. Also provided are methods of improving voluntary muscle control and methods of treating neuropathic pain in a subject having an injury to the nervous system. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
• US7294715B2
  申请人：——

  公开号：US7294715B2

  公开（公告）日：2007-11-13
• [EN] APORPHINE AND OXOAPORPHINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF<br/>[FR] COMPOSÉS APORPHINIQUES ET OXOAPORPHINIQUES ET UTILISATION PHARMACEUTIQUE CORRESPONDANTE
  申请人：LOTUS PHARMACEUTICAL CO LTD

  公开号：WO2007134485A1

  公开（公告）日：2007-11-29

  [EN] The invention provides aporphine and oxoaporphine compounds that may be used to manufacture a medicaments for preventing or treating vascular dysfunction resulting in ischemic and metabolic diseases or preventing complications in human and mammal. The ischemic diseases may include ischemic cerebral apoplexy, ischemic cerebral thrombosis, ischemic cerebral embolism, hypoxic ischemic encephlopathy, ischemic cardiac disease or ischemic enteropathy etc. The metabolic disease may include diabetes-induced vascular diseases, such as hypertension, atherosclerosis, peripheral artery or venous thrombosis, retinopathy and nephropathy. Methods for treating ischemic and metabolic diseases or preventing complications are also disclosed.
  [FR] La présente invention concerne des composés aporphiniques et oxoaporphiniques entrant dans la fabrication de médicaments destinés à la prévention ou au traitement de dysfonction vasculaire aboutissant à des affections ischémiques et métaboliques ou destinés à la prévention de complications chez les humains et les mammifères. Les affections ischémiques concernées sont essentiellement l'apoplexie cérébrale ischémique, la thrombose cérébrale ischémique, l'embolie cérébrale ischémique, l'encéphalopathie ischémique hypoxique, la cardiopathie ischémique ou l'entéropathie ischémique. Les affections métaboliques sont essentiellement les affections vasculaires des diabétiques telles que l'hypertension, l'athérosclérose la thrombose veineuse ou artérielle périphérique, la rétinopathie et la néphropathie. L'invention concerne également des procédés pour le traitement d'affections ischémiques et métaboliques ou la prévention de complications.

表征谱图